Physician profile
Arin E Ford Johnson
NPI 1467623173
$3,526.49
in general payments reported to CMS, 2019-2025
38 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $216 · 2021: $284 · 2022: $602 · 2023: $944 · 2024: $874 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.15 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.23 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $308.66 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $279.83 | 2023-2024 | Myfembree |
| Shield Therapeutics INC | $272.37 | 2022-2025 | Accrufer |
| Astellas Pharma US INC | $242.83 | 2023-2025 | Veozah, Myrbetriq |
| Organon LLC | $217.75 | 2021-2024 | Nexplanon, Nuvaring |
| Hologic Sales and Service, LLC | $182.56 | 2019-2025 | Aptima, Fluent Fluid Management System, Coolseal Generator |
| Agile Therapeutics, INC. | $167.12 | 2021-2024 | Twirla |
| Pfizer INC. | $164.70 | 2021-2025 | |
| Myovant Sciences INC. | $150.63 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.47 | 2019-2025 | |
| Coopersurgical, INC. | $86.33 | 2019-2024 | Paragard T 380a |
| Therapeuticsmd, INC. | $78.47 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $73.56 | 2019-2020 | |
| Lilly USA, LLC | $71.00 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53.08 | 2019 | |
| Exact Sciences Corporation | $47.44 | 2023-2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $46.30 | 2019-2020 | |
| Duchesnay USA Incorporated | $39.44 | 2019 | |
| Gynesonics, INC. | $39.13 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Allergan, INC. | $39.07 | 2019 | |
| Aspira Women'S Health INC | $33.78 | 2021-2022 | |
| Exeltis, USA INC. | $30.53 | 2022-2024 | Slynd |
| Vertical Pharmaceuticals, LLC | $28.69 | 2019 | |
| Millicent US INC | $27.97 | 2024 | Intrarosa, Femring |
| Convatec INC. | $23.88 | 2019 | |
| Amgen INC. | $19.68 | 2020 | |
| Novo Nordisk INC | $17.91 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.80 | 2019 | |
| Hologic INC | $17.26 | 2021 | |
| Dysis Medical, INC. | $16.87 | 2020 | |
| Meditrina | $14.89 | 2023 | |
| Scynexis, INC. | $13.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.88 | 2022 | |
| Mission Pharmacal Company | $13.16 | 2020 | |
| Evofem Biosciences, INC. | $12.83 | 2022 | |
| Avion Pharmaceuticals | $12.46 | 2021 | |
| Lupin INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arin Ford Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.